Other genomic aberrations might act as potent alternative drivers of cancer cell proliferation and invasion in HER2‐negative subclones, such as the previously identified BRF2 and DSN1 gene amplification and the HER2 p.I767M somatic mutation (Ng et al., 2015). The gene discussed is ERBB2; the disease is cancer.